AGR2 Antibody, Biotin conjugated

1. Silencing AGR2 can promote apoptosis and inhibit cell migration, invasion, and chemotherapy resistance in pancreatic cancer cells through the ERK/AKT signaling pathway. PMID: 30055941
2. Serum AGR2 levels can serve as a serum marker for the clinical prognosis of nasopharyngeal carcinoma. However, serum AGR2 levels may not provide advantages in clinical practice for the differential diagnosis of cancer. PMID: 29269202
3. Research suggests that overexpression of MUC13 and loss of AGR2 expression may predict the progression of Intraductal papillary mucinous neoplasm and an unfavorable prognosis in patients with this condition. PMID: 29650332
4. Cytosolic AGR2 contributes to cell metastasis by stabilizing the p65 protein, which subsequently activates NF-kappaB and facilitates epithelial to mesenchymal transition (EMT). PMID: 29410027
5. Data indicates that AGR2 acts as a keeper of epithelial phenotypes, promoting the expression of the epithelial marker E-cadherin and negatively affecting the mesenchymal markers vimentin and N-cadherin. PMID: 28810836
6. Studies have demonstrated that inhibiting either FOXM1 or AGR2 in human PIMAs inhibits mucinous characteristics, reduces tumor growth and invasion. FOXM1 is necessary and sufficient to induce mucinous phenotypes in lung tumor cells in vivo. PMID: 29267283
7. AGR2, secreted by prostate cancer cells, induces programmed cell death in normal cells. PMID: 27283903
8. Secretion and cell surface localization of AGR2 are characteristic of bladder cancer, while the expression of AGR2 alone is not. PMID: 26894971
9. Obesity induces the expression of the mitochondrial form of arginase ARG2 in pancreatic ductal adenocarcinoma. PMID: 28808255
10. Overexpression of AGR2 counteracts the phenotypes induced by miR-342-3p. PMID: 29107102
11. Research has shown that extracellular AGR2 plays an extracellular role independent of its endoplasmic reticulum function and elucidates this gain-of-function as a novel and unexpected critical extracellular matrix microenvironmental pro-oncogenic regulator of epithelial morphogenesis and tumorigenesis. PMID: 27240165
12. High AGR2 expression is associated with ovarian cancer. PMID: 28481872
13. This study demonstrates that AGR2, overexpressed in a variety of human cancers and associated with poor prognosis, up-regulates DUSP10, which subsequently inhibits p38 MAPK and prevents p53 activation by phosphorylation. PMID: 26733232
14. A direct impact of mTOR signaling on AGR2 3'UTR shortening associated with increased protein synthesis has been observed, leading to the identification of a novel molecular mechanism involved in upregulation of AGR2 levels in mTOR-activated cells via modulating the 3'UTR length of AGR2 mRNA. PMID: 28408318
15. Research suggests elevated AGR2 as a candidate tamoxifen-dependent mechanism of action responsible for an increased incidence of endometrial cancer. PMID: 28402678
16. AGR2 can also be upregulated in a hormone-independent manner. AGR2 expression has been shown to be significantly increased in HER2-positive breast tumors at both the mRNA and protein levels. PMID: 28238761
17. Findings have shown that recombinant human endostatin-gold nanoparticles might normalize vessels by interfering with AGR2-mediated angiogenesis in metastatic colorectal cancer. PMID: 28714365
18. All these data clearly show that anterior gradient protein 2 is highly expressed in breast cancer and can be considered a putative biomarker for breast cancer prognosis. PMID: 28671019
19. AGR2, through interaction with ER-alpha, enhances fulvestrant resistance and IGF-1-induced carcinogenesis in breast cancer cells. PMID: 27063095
20. AGR2 inhibits TNF-alpha-induced Caco-2 cell hyperpermeability by regulating tight junctions, and this protective mechanism may be promoted by inhibition of NF-kappaB p65-mediated activation of the MLCK/p-MLC signaling pathway. PMID: 28339048
21. Research has demonstrated the significant role of AGR2 in regulating EMT of glioblastoma. SDF-1 signaling induces the expression of AGR2 to control the progression of EMT in the development of glioblastoma. PMID: 26608373
22. Results show that AGR2 is O-glycosylated upon secretion from human and rat cell lines, and this form of the protein is released from healthy cells and not as a result of cell lysis. PMID: 26169982
23. Nearly all NSCLC tumors show AGR2 expression. Lung cancer expression of AGR2 has prognostic value for younger patients. PMID: 26445321
24. These data together identify the single cysteine of AGR2 as an oxidant-responsive moiety that regulates its propensity for oxidation and its monomeric-dimeric state. PMID: 26876500
25. The prognostic impact of AGR2 expression could be related to treatment outcome in estrogen receptor-positive breast cancers and/or its metastasis-promoting effects. PMID: 25663596
26. This article provides an analysis of the molecular characteristics, function, and regulation of AGR2 in cancer. PMID: 25937245
27. AGR2 was found to be higher in HNSCC than in normal oral mucosa. High levels were associated with the T category, pathological grade, and lymphatic metastasis. AGR2 expression increased in recurring HNSCC after radiotherapy or cisplatin-based chemotherapy. PMID: 25871396
28. The mechanism linking the IGF-1/insulin signal and AGR2 promoter activation is important. PMID: 25956506
29. Data suggests the potential usability of anterior gradient homolog 3 (AGR3) and anterior gradient homolog 2 (AGR2) as biomarkers for blood-based early detection of breast cancer. PMID: 25875093
30. Our findings, for the first time, describe AGR2 as an important regulator in chemical hypoxia-induced doxorubicin resistance in breast cancer cells. PMID: 26079208
31. Relying on available data and in silico analyses, the study shows that AGR2 and AGR3 proteins are co-expressed or uncoupled in context-dependent manners in diverse carcinomas and healthy tissues. PMID: 25666661
32. High AGR2/LGR5 was associated with poor progression-free survival by multivariate analysis. PMID: 22605983
33. Data define the importance of AGR2 in breast cancer cell growth and highlight a mechanism where changes in FOXA1 activity obviate the need for ER in the regulation of this gene. PMID: 25100862
34. Knockdown of anterior gradient 2 expression extenuates tumor-associated phenotypes of SNU-478 ampulla of Vater cancer cells. PMID: 25367337
35. AGR2 is a novel marker of papillary thyroid carcinoma. PMID: 24976026
36. AGR2 splice variant transcripts are potential diagnostic biomarkers for the non-invasive detection of PCa using urine exosomes. PMID: 25237833
37. Expression of anterior gradient 2 is decreased with the progression of human biliary tract cancer. PMID: 25186196
38. AGR2 has both intracellular and extracellular effects in the intestine. PMID: 25111734
39. Anterior gradient 2 downregulation in a subset of pancreatic ductal adenocarcinoma is a prognostic factor indicative of epithelial-mesenchymal transition. PMID: 25418581
40. Results indicate that DNA methylation within the AGR2 promoter modulates more aggressive cancer cell phenotypes. PMID: 24920423
41. Data demonstrates that AGR2 protein has a more dominant action on proteome remodeling rather than transcriptome effects and highlights a dominant effect on p53 pathway attenuation. PMID: 24710632
42. Anterior gradient 2 (AGR2) was overexpressed in human Nasopharyngeal carcinoma (NPC) tissues, particularly in cervical lymph node metastatic nasopharyngeal carcinoma. PMID: 24717913
43. Based on an initial cohort of 37 subjects, urinary AGR2/PSA concentration ratios showed a significant difference (P = 0.026) between noncancer and cancer. PMID: 24251762
44. These data suggest that AGR-2 influences prostate cancer metastasis by regulating cellular adhesion and apoptosis. PMID: 24587138
45. AGR2-mediated lung adenocarcinoma metastasis novel mechanism network through repression with interferon coupling cytoskeleton to steroid metabolism-dependent humoral immune response. PMID: 24960290
46. Increased expression of AGR2 and ERp57 is associated with cancer. [review] PMID: 24490732
47. Data indicates that aberrantly elevated anterior gradient 2 (AGR2) expression predicts poor patient outcome. PMID: 24177142
48. AGR2 is frequently lost in colorectal carcinomas and might be a novel independent prognostic factor for overall patient survival. PMID: 24794000
49. Prostate cancer biomarkers, AGR2 and CD10, can be used in combination to stratify prostate cancer patients for clinical outcome. PMID: 23348903
50. Overexpression of AGR2 showed a positive correlation with oral tumor metastasis. PMID: 23834814

Show More

Hide All

HGNC: 328

OMIM: 606358

KEGG: hsa:10551

STRING: 9606.ENSP00000391490

UniGene: Hs.530009